QuidelOrtho projects $2.7 billion to $2.75 billion in 2026 revenue and $100 million to $120 million in free cash flow, despite China pricing uncertainty

QuidelOrtho projects 2026 revenue between $2.7 billion and $2.75 billion, aiming for $100 million to $120 million in free cash flow. The company's forecast comes despite uncertainty surrounding pricing in China and a softer respiratory season in Q1 2026, with CDC-reported influenza-like illness visits down about 30%. These factors, along with the impact of the LEX acquisition, influenced QuidelOrtho's first-quarter performance and outlook.